P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions.

[1]  D. Cao,et al.  Evolution of drug-eluting coronary stents: a back-and-forth journey from the bench-to-bedside. , 2022, Cardiovascular research.

[2]  Deepak L. Bhatt,et al.  P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention , 2022, Nature Reviews Cardiology.

[3]  M. Valgimigli,et al.  Duration of Antiplatelet Therapy After Complex Percutaneous Coronary Intervention In Patients at High Bleeding Risk: a MASTER DAPT trial sub-analysis. , 2022, European heart journal.

[4]  K. Tanabe,et al.  Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. , 2022, JAMA cardiology.

[5]  Theresa M. Beckie,et al.  2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2021, Circulation.

[6]  Yong Hwan Park,et al.  P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial , 2021, Cardiology journal.

[7]  A. Íñiguez,et al.  Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. , 2021, The New England journal of medicine.

[8]  Y. Jang,et al.  Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Acute Coronary Syndrome Patients With a High Risk of Ischemic Events , 2021, Circulation. Cardiovascular interventions.

[9]  P. Serruys,et al.  P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials , 2021, BMJ.

[10]  S. Pocock,et al.  Impact of Clinical Presentation on Bleeding Risk after Percutaneous Coronary Intervention and Implications for the ARC-HBR Definition. , 2021, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[11]  K. Tanabe,et al.  Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention , 2021, Circulation. Cardiovascular interventions.

[12]  S. Windecker,et al.  SINUS BRADYCARDIA AS THE INITIAL MANIFESTATION OF COVID-19 , 2021, Journal of the American College of Cardiology.

[13]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[14]  Y. Jang,et al.  Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. , 2020, JAMA.

[15]  Samin K. Sharma,et al.  Ticagrelor With Aspirin or Alone After Complex PCI: The TWILIGHT-COMPLEX Analysis. , 2020, Journal of the American College of Cardiology.

[16]  P. Serruys,et al.  Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. , 2019, Journal of the American College of Cardiology.

[17]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[18]  P. Serruys,et al.  Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. , 2019, European heart journal.

[19]  Deepak L. Bhatt,et al.  Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. , 2019, Journal of the American College of Cardiology.

[20]  G. Stone,et al.  Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. , 2018, International journal of cardiology.

[21]  Zhiyun Xu,et al.  Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial , 2018, JAMA.

[22]  Deepak L. Bhatt,et al.  Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials , 2017, The Lancet.

[23]  C. Held,et al.  Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial , 2016, European heart journal.

[24]  Deepak L. Bhatt,et al.  Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. , 2016, Journal of the American College of Cardiology.

[25]  M. Krucoff,et al.  Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. , 2016, JACC. Cardiovascular interventions.

[26]  P. Serruys,et al.  Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials , 2015, Circulation. Cardiovascular interventions.

[27]  Richard D Riley,et al.  Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement , 2015 .

[28]  L. Mauri,et al.  Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial. , 2014, European heart journal.

[29]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.